Takami Sato 研究室

主宰者：Takami Sato

慶應義塾大学

AI 要約（直近 5 年の研究成果）

要約はまだ生成されていません。

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

外部リンク

研究成果（97 件）

[2026] A Phase II Trial of Defactinib Combined with Avutometinib in Patients with Metastatic Uveal Melanoma
DOI: https://doi.org/10.3390/cancers18142232
[2025] Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific
DOI: https://doi.org/10.1016/j.xcrm.2025.102076
[2025] Breaking the Shield: Systematic Security Analysis on Pulse Fingerprinting LiDAR Systems for Autonomous Driving
DOI: https://doi.org/10.1109/jsen.2025.3558401
[2025] Figure S2 from IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression
DOI: https://doi.org/10.1158/1535-7163.30734195
[2025] Figure S7 from IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression
DOI: https://doi.org/10.1158/1535-7163.30734180
[2025] 182 DetermaIO stratifies the tumor microenvironment and immunotherapy response in melanoma: a pilot study including cutaneous and uveal subtypes
DOI: https://doi.org/10.1136/jitc-2025-sitc2025.0182
[2025] Figure S4 from IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression
DOI: https://doi.org/10.1158/1535-7163.30734189
[2025] Figure S6 from IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression
DOI: https://doi.org/10.1158/1535-7163.30734183
[2025] Figure S5 from IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression
DOI: https://doi.org/10.1158/1535-7163.30734186
[2025] Table 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
DOI: https://doi.org/10.1158/1078-0432.30750625

続きを表示（残り 87 件）

[2025] Table 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
DOI: https://doi.org/10.1158/1078-0432.30750631
[2025] Figure 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
DOI: https://doi.org/10.1158/1078-0432.30750637
[2025] Table 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
DOI: https://doi.org/10.1158/1078-0432.30750628
[2025] Figure 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
DOI: https://doi.org/10.1158/1078-0432.30750643
[2025] Supplementary Data 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
DOI: https://doi.org/10.1158/1078-0432.30750634
[2025] Figure 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
DOI: https://doi.org/10.1158/1078-0432.30750640
[2025] Figure S3 from IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression
DOI: https://doi.org/10.1158/1535-7163.30734192
[2025] Figure S1 from IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression
DOI: https://doi.org/10.1158/1535-7163.30734198
[2025] Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients
DOI: https://doi.org/10.1093/oncolo/oyaf323
[2025] Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
DOI: https://doi.org/10.1158/1078-0432.ccr-25-1513
[2025] Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade–resistant melanoma: Final analysis from a phase 1b study
DOI: https://doi.org/10.1002/cncr.70022
[2025] Percutaneous hepatic perfusion (PHP) with melphalan for treatment of liver metastases from uveal melanoma: Initial commercial experience.
DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.e21532
[2025] Immunoembolization for patients with uveal melanoma hepatic metastasis: A single-institution real-world data analysis.
DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.9586
[2025] High-dose 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) chemoembolization for treatment-naïve patients with limited uveal melanoma hepatic metastases.
DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.9550
[2025] On the Realism of LiDAR Spoofing Attacks against Autonomous Driving Vehicle at High Speed and Long Distance
DOI: https://doi.org/10.14722/ndss.2025.230628
[2025] Slamspoof: Practical Lidar Spoofing Attacks on Localization Systems Guided by Scan Matching Vulnerability Analysis
DOI: https://doi.org/10.1109/icra55743.2025.11127495
[2025] From Lab to Road: Realizing and Detecting LiDAR Spoofing Attacks Against Autonomous Vehicles at High Speed and Long Distance
DOI: https://doi.org/10.1109/jsen.2025.3565532
[2025] Abstract 1271: Generation and optimization of humanized mice models in metastatic uveal melanoma
DOI: https://doi.org/10.1158/1538-7445.am2025-1271
[2025] Short Report: The Variants in CHEK2 in Metastatic Uveal Melanoma
DOI: https://doi.org/10.3390/jcm14082815
[2025] Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies
DOI: https://doi.org/10.1016/j.xcrm.2025.101994
[2025] Immune Profiling of Uveal Melanoma Liver Metastases and Response to Checkpoint Inhibitors
DOI: https://doi.org/10.1097/cji.0000000000000558
[2024] On the Vulnerability of Traffic Light Recognition Systems to Laser Illumination Attacks
DOI: https://doi.org/10.14722/vehiclesec.2024.23024
[2024] A Cross-Verification Approach with Publicly Available Map for Detecting Off-Road Attacks against Lane Detection Systems
DOI: https://doi.org/10.14722/vehiclesec.2024.23032
[2024] Demo: Towards Practical LiDAR Spoofing Attack against Vehicles Driving at Cruising Speeds
DOI: https://doi.org/10.14722/vehiclesec.2024.25018
[2024] 694 Phase 1 safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM)
DOI: https://doi.org/10.1136/jitc-2024-sitc2024.0694
[2024] Intriguing Properties of Diffusion Models: An Empirical Study of the Natural Attack Capability in Text-to-Image Generative Models
DOI: https://doi.org/10.1109/cvpr52733.2024.02326
[2024] Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress
DOI: https://doi.org/10.1126/scisignal.adn8376
[2024] Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
DOI: https://doi.org/10.1136/jitc-2024-009028
[2024] Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM).
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.9507
[2024] Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM).
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.9529
[2024] Real world tebentafusp-tebn experience at a tertiary care referral center.
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e21526
[2024] Geospatial analysis of the distribution of uveal melanoma patients at a referral center in the United States.
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e21566
[2024] A rat-based preclinical platform facilitating transcatheter hepatic arterial infusion in immunodeficient rats with liver xenografts of patient-derived pancreatic ductal adenocarcinoma
DOI: https://doi.org/10.1038/s41598-024-61142-y
[2024] Abstract CT260: A phase II trial of defactinib combined with avutometinib in patients with metastatic uveal melanoma
DOI: https://doi.org/10.1158/1538-7445.am2024-ct260
[2024] Abstract 6903: Treatment efficacy of transcatheter hepatic arterial infusion chemotherapy with cisplatin in a severe immunodeficient rat model with patient-derived primary pancreatic ductal adenocarcinoma xenografted into the liver
DOI: https://doi.org/10.1158/1538-7445.am2024-6903
[2024] Abstract 1529: Development of lymphoid aggregates in metastatic uveal melanoma tumors treated with tebentafusp
DOI: https://doi.org/10.1158/1538-7445.am2024-1529
[2024] Abstract No. 28 Chemoembolization (TACE) with High-Dose 1,3-Bis-(2-Chloroethyl)-1-Nitrosourea (BCNU) for First-Line Treatment of Limited Uveal Melanoma Hepatic Metastases
DOI: https://doi.org/10.1016/j.jvir.2023.12.050
[2024] LiDAR Spoofing Meets the New-Gen: Capability Improvements, Broken Assumptions, and New Attack Strategies
DOI: https://doi.org/10.14722/ndss.2024.23350
[2024] WIP: Towards Practical LiDAR Spoofing Attack against Vehicles Driving at Cruising Speeds
DOI: https://doi.org/10.14722/vehiclesec.2024.23023
[2024] Invisible Reflections: Leveraging Infrared Laser Reflections to Target Traffic Sign Perception
DOI: https://doi.org/10.14722/ndss.2024.241053
[2024] WIP: Adversarial Retroreflective Patches: A Novel Stealthy Attack on Traffic Sign Recognition at Night
DOI: https://doi.org/10.14722/vehiclesec.2024.23025
[2024] A cluster of Candida parapsilosis displaying fluconazole-trailing in a neonatal intensive care unit successfully contained by multiple infection-control interventions
DOI: https://doi.org/10.1017/ash.2024.77
[2023] Quality-of-life measurement in high-risk patients with uveal melanoma receiving adjuvant sunitinib or valproic acid.
DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.e18692
[2023] HLA discordance between blood and tumor: A treatment conundrum?
DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.e21577
[2023] Abstract LB118: Evidence of tumor response in orbital lesions treated with tebentafusp in metastatic uveal melanoma patients
DOI: https://doi.org/10.1158/1538-7445.am2023-lb118
[2023] Abstract CT223: Long-term survival follow-up of tebentafusp in previously treated metastatic uveal melanoma (mUM)
DOI: https://doi.org/10.1158/1538-7445.am2023-ct223
[2023] WIP: Infrared Laser Reflection Attack Against Traffic Sign Recognition Systems
DOI: https://doi.org/10.14722/vehiclesec.2023.23055
[2023] WIP: Practical Removal Attacks on LiDAR-based Object Detection in Autonomous Driving
DOI: https://doi.org/10.14722/vehiclesec.2023.23036
[2023] Learning Representation for Anomaly Detection of Vehicle Trajectories
DOI: https://doi.org/10.1109/iros55552.2023.10342070
[2023] Liver Transplantation in a Woman with Mahvash Disease
DOI: https://doi.org/10.1056/nejmoa2303226
[2023] Semi-supervised Semantics-guided Adversarial Training for Robust Trajectory Prediction
DOI: https://doi.org/10.1109/iccv51070.2023.00754
[2023] Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth
DOI: https://doi.org/10.3390/cancers15133451
[2023] Preapproval medical products in patients with the diagnosis of metastatic uveal melanoma.
DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.e21502
[2022] IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression
DOI: https://doi.org/10.1158/1535-7163.mct-22-0147
[2022] Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases
DOI: https://doi.org/10.3389/fonc.2022.961517
[2022] Abstract 50: Multi-omics and immune cell profiling of metastatic uveal melanomas
DOI: https://doi.org/10.1158/1538-7445.am2022-50
[2022] Conditional survival of uveal melanoma using The Cancer Genome Atlas (TCGA) classification (Simplified Version) in 1001 cases
DOI: https://doi.org/10.4103/sjopt.sjopt_69_21
[2022] Randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma: The final analysis of cohort 1.
DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.9586
[2022] Immune profiling of metastatic uveal melanoma and response to immune checkpoint inhibitors.
DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.9565
[2022] Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
DOI: https://doi.org/10.1158/1078-0432.ccr-22-0339
[2022] Improved Uveal Melanoma Copy Number Subtypes Including an Ultra–High-Risk Group
DOI: https://doi.org/10.1016/j.xops.2022.100121
[2022] A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma
DOI: https://doi.org/10.1089/cbr.2021.0366
[2022] WIP: On Robustness of Lane Detection Models to Physical-World Adversarial Attacks
DOI: https://doi.org/10.14722/autosec.2022.23037
[2022] Demo: Remote Adversarial Attack on Automated Lane Centering
DOI: https://doi.org/10.14722/autosec.2022.23015
[2022] Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma
[2022] 92. Characterization of an ultra-high-risk uveal melanoma copy number subtype
DOI: https://doi.org/10.1016/j.cancergen.2022.10.095
[2022] Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
DOI: https://doi.org/10.1038/s41591-022-02015-7
[2021] A case of meningitis due to extensively drug-resistant Pseudomonas aeruginosa imported through medical evacuation: genomic and environmental investigation
DOI: https://doi.org/10.1093/jtm/taab047
[2021] Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ -Driven Uveal Melanoma
DOI: https://doi.org/10.1158/1078-0432.ccr-20-3363
[2021] Demo: Security of Deep Learning based Automated Lane Centering under Physical-World Attack
DOI: https://doi.org/10.14722/autosec.2021.23026
[2021] Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).
DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.9531
[2021] Clinical trial in progress: Phase II trial of defactinib (VS-6063) combined with VS-6766 (CH5126766) in patients with metastatic uveal melanoma.
DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.tps9588
[2021] Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts).
DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.e21513
[2021] WIP: Deployability Improvement, Stealthiness User Study, and Safety Impact Assessment on Real Vehicle for Dirty Road Patch Attack
DOI: https://doi.org/10.14722/autosec.2021.23027
[2021] Demo: Security of Camera-based Perception for Autonomous Driving under Adversarial Attack
DOI: https://doi.org/10.14722/autosec.2021.23018
[2021] A Study Of Hepatic Internal Radiation with Yttrium90 Resin Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Uveal Melanoma Metastatic to the Liver
DOI: https://doi.org/10.2139/ssrn.3885645
[2021] Abstract CT038: Kinetics of radiographic response for tebentafusp (tebe) in previously treated metastatic uveal melanoma (mUM) patients (pts) achieving prolonged survival
DOI: https://doi.org/10.1158/1538-7445.am2021-ct038
[2021] Abstract 1137: PRMT5 inhibition regulates alternative splicing and DNA damage repair pathways in SF3B1 R625G expressing uveal melanoma cells
DOI: https://doi.org/10.1158/1538-7445.am2021-1137
[2021] Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs
DOI: https://doi.org/10.1016/j.jbc.2021.101033
[2021] Abstract CT032: CMP-001 demonstrates improved response in noninflamed anti-PD-1 refractory melanoma and response is associated with serum CXCL10
DOI: https://doi.org/10.1158/1538-7445.am2021-ct032
[2021] Phase 1 trial of a novel, first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in patients with advanced or recurrent treatment-refractory solid malignancies.
DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.3084
[2021] Prognostic Values of G-Protein Mutations in Metastatic Uveal Melanoma
DOI: https://doi.org/10.3390/cancers13225749
[2021] 950 Final analysis: phase 1b study investigating intratumoral injection of toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma
DOI: https://doi.org/10.1136/jitc-2021-sitc2021.950
[2021] 538 Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp
DOI: https://doi.org/10.1136/jitc-2021-sitc2021.538
[2021] Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
DOI: https://doi.org/10.1136/jitc-2021-003272
[2021] Orthotopic Human Metastatic Uveal Melanoma Xenograft Mouse Models: Applications for Understanding the Pathophysiology and Therapeutic Management of Metastatic Uveal Melanoma
DOI: https://doi.org/10.1002/cpz1.110
[2021] Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma
DOI: https://doi.org/10.3390/cancers13051104

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。

AI 要約（直近 5 年の研究成果）

外部リンク

関連研究室(8 件)

研究成果（97 件）

科研費（0 件）

所属学会・役職（0 件）